BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 administered monthly achieved a statistically significant 62.3% reduction in low-density lipoprotein cholesterol levels after 28 weeks compared to placebo, meeting the study’s primary efficacy endpoint.

ClearPoint Neuro, Inc. announced its Swedish partner, Clinical Laserthermia Systems, has received 510 clearance for its laser which the Company plans to commercialize as the ClearPoint Prism™ Neuro Laser Therapy System.

Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced the appointment of Brenda Van Vreeswyk as Head of Human Resources.

After seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Amryt announces its support today for FH Awareness Day 2022 which will take place on Saturday, September 24, 2022.

Allogene Therapeutics, Inc. today announced that management plans to present at the Jefferies Cell and Genetic Medicine Summit on Friday, September 30, 2022 at 6:30AM Pacific Time/9:30AM Eastern Time.

SAB Biotherapeutics announced today that the Company will present new data on its fully-human polyclonal antibody platform’s ability to maintain its efficacy against multiple variants of several highly mutating viruses at the Options for Control of Influenza (OPTIONS XI) conference, which is hosted by the International Society for Influenza and other Respiratory Virus Diseases (ISIRV) in Belfast, Northern Ireland, from Sept. 26-29, 2022.

According to Nova one advisor, the global Hemodialysis and Peritoneal Dialysis market was valued at USD 88.20 billion in 2021 and it is expected to hit around USD 156.63 billion by 2030 with a CAGR of 6.65% during the forecast period 2022 to 2030.

InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”) announced today the appointment of R. Rimmy Malhotra, a new independent director to InfuSystem’s Board of Directors, effective September 20, 2022.

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced the official opening of its office and research facilities at the Singapore Science Park.